News · TORNTPHARM · 10 Jul 2026 · Amit Lamba
Torrent Pharma Initiates Voluntary Recall for Select Semalix Injection Pens
Torrent Pharmaceuticals Limited announced a precautionary voluntary recall for specific batches of its Semalix injection disposable pens, citing a technical evaluation from its manufacturer.
Lead
Torrent Pharmaceuticals Limited has initiated a voluntary recall for select batches of its Semalix injection disposable pens. This precautionary measure, announced on July 9, 2026, follows a product recall notification issued by Dr. Reddy's Laboratories Ltd. (DRL), the manufacturer of the affected batches, for a technical evaluation. The company emphasized that patient safety remains paramount, stating there is no risk to patients already undergoing treatment with these products due to the recall.
Key highlights
- Voluntary recall applies to select batches of Semalix injection disposable pens (2 mg and 4 mg).
- The action is a precautionary measure based on a technical evaluation by manufacturer Dr. Reddy's Laboratories Ltd.
- Torrent Pharmaceuticals stated there is no risk to patients currently on the treatment.
- All other Semaglutide SKUs, including oral formulations and other injection strengths/manufacturers, remain unaffected.
- Unaffected products include Semalix tablets (3 mg, 7 mg, 14 mg), Sembolic tablets (3 mg, 7 mg, 14 mg), Semalix injection (8 mg manufactured by MSN Laboratories), and Sembolic re-usable injection (manufactured by Zydus Lifesciences Ltd.).
What drove it
The recall was prompted by a product recall notification from Dr. Reddy's Laboratories Ltd., the manufacturer of the affected Semalix injection disposable pens. The filing specified that this action was taken as a precautionary measure for a technical evaluation. Torrent Pharmaceuticals Limited did not elaborate further on the specifics of the technical evaluation.
Why it matters
This voluntary recall demonstrates Torrent Pharmaceuticals Limited's responsiveness to product quality concerns originating from its manufacturing partners. By taking swift action in response to the manufacturer's notification, the company aims to uphold product integrity and patient trust. The explicit mention that patient safety is not compromised for those already on treatment, and that the recall is limited to specific batches and manufacturers, helps clarify the scope of the issue.
What to watch
Stakeholders will likely monitor any further updates from Torrent Pharmaceuticals Limited or Dr. Reddy's Laboratories Ltd. regarding the outcome of the technical evaluation or the completion of the recall process. (Source: Exchange filing)
See full P&L, ratios, and valuation on Bull Karma
10-year financials from NSE/BSE exchange filings for TORNTPHARM.
View financial statementsLatest news
- JSW Steel Releases Investor Presentation for Q1 FY26-27 Results
JSWSTEEL · 18 Jul 2026 (Yesterday)
- RBL Bank Reports 27% Net Profit Growth in Q1 FY26-27, Capital Adequacy Rises Significantly
RBLBANK · 18 Jul 2026 (Yesterday)
- SAGILITY Communicates TDS Rules for FY2025-26 Final Dividend
SAGILITY · 18 Jul 2026 (Yesterday)
- Tata Elxsi crosses INR1,000 crore quarterly revenue mark in Q1 FY26-27
TATAELXSI · 18 Jul 2026 (Yesterday)
- Wipro Q1 FY26-27 Earnings Call Transcript Highlights AI Strategy and Market Trends
WIPRO · 18 Jul 2026 (Yesterday)
Figures sourced from public NSE/BSE exchange filings. Not investment advice. Editorial policy